ゼリア新薬工業（4559） – Summary of Financial Results for the third quarter 2022

Quarterly Financial Summary (For the first nine months of the fiscal year ending March 31, 2022) [Under Japanese GAAP] (Consolidated) February 2, 2022 (Stock Exchange: First Section of Tokyo Stock Exchange) (URL: https://www.zeria.co.jp/) TEL (03) 3661-1039 Listed Company: Zeria Pharmaceutical Co., Ltd. Code Number: 4559 Representative: Mitsuhiro Ibe, Representative Director, President & COO Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division Scheduled date to submit the Quarterly Securities Report: Scheduled date to commence dividend payments: Preparation of supplementary documents to the quarterly financial results: Holding of quarterly financial results presentation: February 4, 2022 – None None 1. Consolidated Financial Highlights (April 1, 2021 through December 31, 2021) (1) Consolidated Financial Results (cumulative) (Amounts under a million yen are truncated.) (Percentage figures indicate changes from the same period of the previous year.) Net sales Operating profit Ordinary profit Profit attributable to owners of parent Nine months ended Million yen % Million yen % Million yen % Million yen December 31, 2021 45,104 11.7 December 31, 2020 40,370 – 5,495 3,879 41.6 – 5,613 3,561 57.6 – 4,043 3,702 % 9.2 – Note: Comprehensive income: For the nine months ended December 31, 2021: 2,169 million yen [(45.8)%] For the nine months ended December 31, 2020: 4,001 million yen [–%] Basic earnings per share Diluted earnings per share Nine months ended December 31, 2021 December 31, 2020 Yen 89.33 80.18 Yen – – Note: The Company has applied the “Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29, March 31, 2020) and relevant revised ASBJ regulations from the start of the first quarter of the fiscal year ending March 31, 2022, and each figure for the nine months ended December 31, 2020, is the figure after retrospectively applying the accounting standard and relevant revised ASBJ regulations. Consequently, the percentage of year-on-year change of each figure for the nine months ended December 31, 2020, is not shown. (2) Consolidated Financial Position As of Total assets Net assets Equity ratio Net assets per share Million yen Million yen December 31, 2021 March 31, 2021 125,981 121,860 55,496 56,152 % 43.9 45.9 Yen 1,228.23 1,225.09 Reference: Equity: As of December 31, 2021: 55,313 million yen Note: The Company has applied the “Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29, March 31, 2020) and relevant revised ASBJ regulations from the start of the first quarter of the fiscal year ending March 31, 2022, and each figure as of March 31, 2021, is the figure after retrospectively applying the accounting standard and relevant revised ASBJ regulations. As of March 31, 2021: 55,985 million yen 2. Dividends Year ended March 31, 2021 Year ending March 31, 2022 Year ending March 31, 2022 (Forecast) First quarter Second quarter Third quarter Year-end Total Annual dividends Yen – – Yen 17.00 17.00 Yen – – Yen 17.00 17.00 Note: Revision of the forecast of dividends most recently announced: None 3. Consolidated Financial Forecast for the Fiscal Year Ending March 31, 2022 (April 1, 2021 through March 31, 2022) Net sales Operating profit Ordinary profit (Percentage figures indicate year-on-year changes.) Profit attributable to owners of parent Basic earnings per share Million yen % Million yen % Million yen % Million yen % Full year 60,000 13.7 5,300 52.5 5,200 62.1 3,700 17.7 Note: Revision of the financial forecast most recently announced: None Year-on-year changes are presented in comparison with figures from the previous fiscal year after retrospective adjustments as retrospective adjustments were carried out due to changes in accounting policies. * Notes (1) Significant changes of subsidiaries during the nine months ended December 31, 2021 (changes in specified subsidiaries resulting in changes in scope of consolidation): None Inclusion: – (Company name: –) Exclusion: – (Company name: –) (2) Application of special accounting for preparing the quarterly consolidated financial statements: Yes (3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections 1) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes 2) Changes in accounting policies due to other reasons: None 3) Changes in accounting estimates: None 4) Restatement of prior period financial statements after error corrections: None (4) Number of shares issued (common shares) 1) Number of shares issued as of the end of the period (including treasury shares): As of December 31, 2021: 53,119,190 shares As of March 31, 2021: 53,119,190 shares 2) Number of treasury shares as of the end of the period: As of December 31, 2021: 8,084,330 shares As of March 31, 2021: 7,420,461 shares 3) Average number of shares during the period (cumulative from the beginning of the fiscal year): For the nine months ended December 31, 2021: 45,266,623 shares For the nine months ended December 31, 2020: 46,174,949 shares Yen 34.00 34.00 Yen 81.84 * Quarterly Financial Summary Is Exempt from Quarterly Review Conducted by Certified Public Accountants or An Audit Corporation. * Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors.